National Institute For Infectious Diseases Lazzaro Spallanzani

3 trials 1 recruiting Academic / non-commercial

Filter these 3 trials by condition, phase, country and more.

Open in Search →

3 Registered trials

1 Recruiting

0 Completed trials

1 Countries active

6 Unique IMPs

N/A Results reported

Phase II

Phase IV

Phase II: 2 Phase IV: 1

Top IMPs

MERCAPTAMINE 2 CILGAVIMAB 1 ELASOMERAN 1 SARS-COV-2, SPIKE PROTEIN, RECOMBINANT, EXPRESSED IN SF9 CELLS DERIVED FROM SPODOPTERA FRUGIPERDA 1 SOTROVIMAB 1 TOZINAMERAN 1

All trials

3 total

Temporal kinetics of antibody and cellular response markers and relative impact of revaccination in patients recovered from COVID-19 after t… Pending

2024-514071-17-00 Phase IV 1 country CILGAVIMAB; ELASOMERAN; SARS-COV-2, SPIKE PROTEIN, RECOMBINANT, EXPRESSED IN SF9…
Cysteamine in association with standard therapy for the treatment of hospitalized patients with COVID-19 pneumonia: phase 2 study on safety … Pending

2024-516800-40-00 Phase II 1 country MERCAPTAMINE
Phase II study on the safety and efficacy of cysteamine in association with standard tuberculosis therapy for the treatment of patients with… Recruiting

2024-516088-10-00 Phase II 1 country MERCAPTAMINE

Showing 1–3 of 3 trials

← All sponsors A–Z